Cortes JE, Goldberg SL, Michallet M, et al. Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice. ASH 59th Annual Meeting & Exhibition, abstract 2894.
Eerder behandelen met ruxolitinib lijkt overlevingsvoordeel van MF-patiënten met int-2 of hoog risico te vergroten
okt 2017 | MPN